Hoth Therapeutics (HOTH) shares advanced nearly 24% in recent Tuesday trading after the company said preliminary results of a preclinical study suggested that its HT-KIT drug inhibits and stabilizes tumor growth.
The study was undertaken through a sponsored scientific research agreement with NC State University, the company said.
Hoth said initial findings showed minimal changes in tumor volumes in treated animals, suggesting that the drug inhibited tumor growth. Tumor sizes were also consistent across the treated animals, indicating the drug's potential reproducibility and reliability, the company added.
Price: 1.09, Change: +0.21, Percent Change: +23.86
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。